Senores Pharmaceuticals Ltd. · NSE:SENORES
Senores Pharmaceuticals — H1 FY26 Earnings Presentation
41 slides from Senores Pharmaceuticals's earnings presentation, November 2025
Slide 1: Investor Presentation November 2025
Investor Presentation November 2025
Slide 2: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Senores Pharmaceuticals Limited (the “Company” / “SPL”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscri
Slide 3: Financial Highlights Q2 & H1 FY26
Financial Highlights Q2 & H1 FY26 Private & Confidential
Slide 4: Key Highlights Q2 & H1FY26
Key Highlights Q2 & H1FY26 Positive Cash Flow Strong Growth in Regulated Strong Growth in Branded Operations Markets business Generics business Cash Flow from Operations Stood at Regulated Markets revenue grew by Branded Generics revenue grew ~Rs. 31 Crs for H1FY26 ~78% on Y-o-Y basis in H1FY26 ~7.6
Slide 5: Key Operational Highlights
Key Operational Highlights * Regulated Markets Emerging Markets 32 81 394 Own Commercial ANDA Products Approved ANDA Products Approved Products 70 50 824 Pipeline Products Pipeline CGT Opportunity Products Products Under Registration 32 45 40 + CDMO/CMO Commercial Products CDMO/CMO Pipeline Products
Slide 6: Consolidated Financial Highlights – Q2 & H1 FY26
Consolidated Financial Highlights – Q2 & H1 FY26 Income (Rs. Crs)* EBITDA (Rs. Crs) PAT (Rs. Crs) +66% +88% +114% 299.8 83.7 51.3 113% 131% 61% 181.0 49.5 30.1 161.8 44.6 24.0 100.6 23.3 13.1 Q2FY25 Q2FY26 H1FY25 H1FY26 Q2FY25 Q2FY26 H1FY25 H1FY26 Q2FY25 Q2FY26 H1FY25 H1FY26 Gross Profit Margin (%)
Slide 7: Business Segment Financial Highlights – Q2 & H1 FY26
Business Segment Financial Highlights – Q2 & H1 FY26 Segment Revenue (INR Cr) Q2FY26 Q2FY25 Y-o-Y Q1FY26 Q-o-Q H1FY26 H1FY25 Y-o-Y Regulated Markets 106.9 57.2 86.9% 90.1 18.6% 196.9 110.4 78.4% Emerging Markets 31.7 36.6 -13.4% 29.0 9.2% 60.7 58.6 3.6% Branded Generics 11.9 0.8 1337.3% 8.2 44.6% 20
Slide 8: Management Commentary
Management Commentary Commenting on the Q2 & H1 FY26 performance, Mr. Swapnil Shah, Managing Director of Senores Pharmaceuticals Limited said, “Building on the momentum from previous quarters, we delivered a strong performance in Q2FY26, with revenues rising 61% and profit after tax growing 131% yea
Slide 9: Consolidated Profit & Loss Account – Q2 & H1 FY26
Consolidated Profit & Loss Account – Q2 & H1 FY26 Consolidated P&L (Rs. Crs) Q2 FY26 Q2 FY25 Y-o-Y Q1FY26 Q-o-Q H1 FY26 H1 FY25 Y-o-Y Revenue from Operations 153.4 98.3 56.1% 130.3 283.7 177.8 59.6% Other Operating Income 8.4 2.4 7.7 16.1 3.3 Total Income 161.8 100.6 60.8% 138.0 17.2% 299.8 181.0 65
Slide 10: Consolidated Balance Sheet
Consolidated Balance Sheet ASSETS (INR Crs) Sep-25 Mar-25 EQUITY AND LIABILITIES (INR Crs) Sep-25 Mar-25 Non-Current Assets Equity Property, Plant and Equipment 235.7 198.9 Equity Share Capital 46.1 46.1 Capital Work-in-Progress 16.0 44.2 Other Equity 768.0 740.1 Goodwill Total Shareholder’s Fund 81
Slide 11: Consolidated Abridged Cash Flow Statement
Consolidated Abridged Cash Flow Statement Cash Flow Statement (INR Crs) H1FY26 H1FY25 Profit/(Loss) Before Tax 67.1 29.4 Adjustments for Non-Cash and Non-Operational Expenses / (Incomes) 7.8 14.6 The company generated ₹31.4 crore in operating cash flow for Operating Profit / (Loss) Before Working Ca
Slide 12: Update on Utilization of Funds from IPO
Update on Utilization of Funds from IPO Amount as proposed in the Amount utilized as on Sep Amount Unutilized as on Sep Sr. No. Object as per Offer Document Offer revised 30, 2025 30, 2025 (Rs. Crs) (Rs. Crs) (Rs. Crs) Investment in one of our Subsidiaries, Havix, to fund capital expenditure 1 requi
Slide 13: Historical Financial Highlights
Historical Financial Highlights Private & Confidential
Slide 14: Historical Profit & Loss Account
Historical Profit & Loss Account Profit and Loss (Rs. Crs) H1FY26 FY25 FY24* YoY Revenue from Operations 283.7 378.0 209.0 80.9% Other Operating Income 16.1 32.4 5.6 Total Income 299.8 410.4 214.5 91.3% Total COGS 118.4 180.7 106.1 Gross Profit 181.3 229.7 108.4 111.9% Gross Margin (%) 60.5% 56.0% 5
Slide 15: Historical Balance Sheet
Historical Balance Sheet ASSETS (Rs. Crs) Mar-25 Mar-24 EQUITY AND LIABILITIES (Rs. Crs) Mar-25 Mar-24 Non-Current Assets Equity Property, Plant and Equipment 198.9 152.2 Equity Share Capital 46.1 30.5 Capital Work-in-Progress 44.2 17.8 Other Equity 740.1 173.8 Goodwill 38.2 38.2 Total Shareholder’s
Slide 16: Historical Abridged Cash Flow Statement
Historical Abridged Cash Flow Statement Cash Flow Statement (INR Crs) H1FY26 FY25 FY24* Profit/(Loss) Before Tax 67.1 70.6 24.9 Adjustments for Non-Cash and Non-Operational Expenses / (Incomes) 7.8 27.1 17.9 Operating Profit / (Loss) Before Working Capital Changes 74.9 97.7 42.8 Changes in Working C
Slide 17: About Senores Pharmaceuticals Limited
About Senores Pharmaceuticals Limited Private & Confidential
Slide 18: Introduction to Senores Pharma
Introduction to Senores Pharma Brief Overview At a Glance Global Research driven Formulation Focused company engaged in developing & manufacturing of pharmaceutical products predominantly for the Regulated Markets of the US, Canada & UK across various therapeutic areas Niche Product Identification C
Slide 19: Business Segments
Business Segments 66% 20% 14% H1 FY26 Income Rs. 300 Crs Regulated Markets Emerging Markets Others Regulated Markets Business Emerging Markets Business Develop & manufacture pharmaceutical products for the Primarily serves the US, Canada and United Kingdom Emerging Markets USFDA approved facility in
Slide 20: Key Events & Milestones
Key Events & Milestones Consolidated presence in emerging Commenced manufacturing activities at Incorporated as “Senores markets by acquiring shares in its greenfield API plant located at Incorporated a wholly owned subsidiary, Pharmaceuticals Pvt. Ltd.” in India. Ratnatris Pharmaceuticals Pvt. Ltd.
Slide 21: Key Strengths
Key Strengths Private & Confidential
Slide 22: Key Strengths of the Company
Key Strengths of the Company 1 Distinct specialty and complex product portfolio built in a short span for Regulated Markets 2 Long-term marketing arrangements with pharmaceutical companies in the Regulated Markets 3 Presence in the Emerging Markets with portfolio, including specialty and complex pro
Slide 23: Distinct Specialty & Complex Product Portfolio Built in a Short Span for Regulated Markets
1 Distinct Specialty & Complex Product Portfolio Built in a Short Span for Regulated Markets Demonstrated Capability to propel Products from Conception to Commercialization ANDA Products Product Identification Product Development Commercial Data Analysis – IQVIA, R&D to establish API Concurrent Part
Slide 24: Presence in Regulated Markets through Long-term marketing arrangements
2 Presence in Regulated Markets through Long -term marketing arrangements MARKETED PRODUCTS CDMO / CMO Business Model Business Model Identify, Develop & Commercialize specialty & complex Customized formulation, development & manufacturing niche products in mid - market range capabilities for custome
Slide 25: Presence in the Emerging Markets with Portfolio Including Specialty and Complex Products
3 Presence in the Emerging Markets with Portfolio Including Specialty and Complex Products Special Focus Niche & Specialty patented products in the US with early launch 561 opportunity in Emerging Markets 96 South East 40+ Commonwealth of Asia Countries Sugammadex Ferric Independent Marketed States
Slide 26: Partners to Global Pharmaceutical Companies in Regulated & Emerging Markets
Partners to Global Pharmaceutical Companies in Regulated & Emerging Markets 26
Slide 27: Strong R&D Capabilities Driving Differentiated Product Portfolio
Strong R&D Capabilities Driving Differentiated Product Portfolio R&D Site 1 - USA Identify Oral Oral ▪ Internal research ORS Injectables API Solids Liquids ▪ In-House R&D in US ▪ Information available for Controlled on subscribed Substances databases R&D Site 2 - India Team ▪ Helps in dossier ▪ 71 p
Slide 28: Accredited Manufacturing Facilities
5 Accredited Manufacturing Facilities Atlanta Facility Ahmedabad, Chhatral Facility Facility 378,943 Sq. Ft. Total Area 2 Manufacturing Lines 12 185,300 Sq. Ft. Manufacturing Lines Total Area OSD 4 Dosage Forms 1.2 Bn units Annual Installed General Oral Beta Lactum Capacity Strong Regulatory Track R
Slide 29: Corporate Structure
Corporate Structure Group holding company based in India Houses Domestic Branded Generics business & API business Senores Pharmaceuticals Inc. Marketing cum ANDA Havix Group Inc Ratnatris Pharmaceuticals Pvt. Ltd. Caters to Regulated Market Caters to Emerging Market Holding Company US based company
Slide 30: Professional and Dedicated Management Team
6 Professional and Dedicated Management Team Swapnil Jatinbhai Shah Sanjay Shaileshbhai Majmudar Deval Rajnikant Shah Promoter & Managing Director Chairman & Non-Executive, Non- Whole-Time Director & CF O Independent Director ▪ 17+ years of experience in the pharma sector ▪ 40+ years of experience ▪
Slide 31: Growth Strategies
Growth Strategies Private & Confidential
Slide 32: Key Strategies
Key Strategies Inorganic growth Significantly enhance market through synergistic presence in North America & acquisitions other Regulated Markets Integrated approach by Launch products with the enhancing capabilities for potential of NDA approval in backward integration the US Strategic alliance for
Slide 33: Enhance Market Presence of Marketed Products in North America and Other Regulated Markets
Enhance Market Presence of Marketed Products in North America and Other Regulated Markets US accounts for 43% of the global pharma market, 56% of the regulated market & 91% Persistent drug shortage calls for an of North America Market increased supply of generic drugs Global pharma market by classif
Slide 34: Entering into Strategic Alliance for CMO/CDMO in Regulated Markets
Entering into Strategic Alliance for CMO/CDMO in Regulated Markets CDMO market growing faster than the pharma market Strategic alliance for CMO/CDMO in Regulated Markets which is growing at 7.7% US CDMO/CMO market (USD bn) The dependence on CDMO/CMO’s has increased as they offer 7.7% Appended Manufa
Slide 35: Expanding into New Regulated & Emerging Markets
Expanding into New Regulated & Emerging Markets Regulated & Emerging markets witnessing strong growth Global pharma market by classification (USD bn) Emerging pharma market by Product (2028F) Regulated pharma market by Product (2028F) Regulated Emerging Innovator Generic Generic Innovator 541.0 376.
Slide 36: Enhancing Capabilities for Backward Integration
Enhancing Capabilities for Backward Integration Indian API export market to grow at a CAGR of 8.4% Pursuing an integrated approach for greater backward integration API exports (USD bn) Setup Greenfield unit - Increase API manufacturing capacity CAGR: 8.4% Proposed from 25 MTPA to 169 MTPA 7.1 Expans
Slide 37: Industry Overview
Industry Overview Private & Confidential
Slide 38: Global Pharma Market
Global Pharma Market Global pharma market is expected to grow at …regulated market will continue to dominate the US continues to exert influence on Global pharma market 6.6% from 2023-28… global pharma market Global pharma market by product type (USD bn) Global pharma market by region (USD bn) Share
Slide 39: Regulated Pharma Market
Regulated Pharma Market Regulated markets to dominate the global pharmaceutical sector, driven by their access to a growing innovative drug market & a thriving generics market Regulated markets constitute 77% of the global North America accounts for 62% of regulated New generics and patent expiratio
Slide 40: Emerging Pharma Market
Emerging Pharma Market Emerging pharma market Overview of India pharma market Emerging markets to outpace developed ones… IPM is amongst the fastest growing in the Oral solids will dominate IPM world… Emerging pharma market size (USD bn) Indian pharma market size (USD bn) Indian pharma market by dos
Slide 41: Senores Pharmaceuticals Limited – Contact Us
SENORES PHARMACEUTICALS LIMITED CONTACT US Senores Pharmaceuticals Limited Strategic Growth Advisors Private Limited CIN: L24290GJ2017PLC100263 CIN: U74140MH2010PTC204285 Mr. Deval Shah – Whole Time Director & CFO Mr. Sagar Shroff / Mr. Tanay Shah sagar.shroff@sgapl.net / tanay.shah@sgapl.net +91 98
Senores Pharmaceuticals — H1 FY26 Earnings Presentation on 6ix